Metraipolis › archive › dc_5ea6463d3920

Pharmacovigilance analysis of cutaneous adverse drug reactions for cetuximab, panitumumab, and necitumumab based on EudraVigilance and WHO VigiAccess — Europe PMC PMID:42358356

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42358356
DOI
10.3389/fphar.2026.1791359
License (as archived)
solo-consultazione
Archived
2026-10-31T15:05:14.160Z
SHA-256 of the archived text
380acff8f59cb4903be98eab7e4be66f59954ff51d4159b180aebddc32b49fc1
Stable URL of this page
https://metraipolis.com/documento/dc_5ea6463d3920

How to cite

Pharmacovigilance analysis of cutaneous adverse drug reactions for cetuximab, panitumumab, and necitumumab based on EudraVigilance and WHO VigiAccess — Europe PMC PMID:42358356 — Europe PMC (en), https://europepmc.org/article/MED/42358356 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5ea6463d3920 (Metraipolis archive dc_5ea6463d3920, sha256 380acff8f59cb4903be98eab7e4be66f59954ff51d4159b180aebddc32b49fc1)
BibTeX
@misc{dc5ea6463d3920,
  title = {Pharmacovigilance analysis of cutaneous adverse drug reactions for cetuximab, panitumumab, and necitumumab based on EudraVigilance and WHO VigiAccess — Europe PMC PMID:42358356},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42358356},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5ea6463d3920; sha256 380acff8f59cb4903be98eab7e4be66f59954ff51d4159b180aebddc32b49fc1},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42358356. Agents can read the archived copy with the MCP tool read_document.